IL128765A0 - Pharmaceutical compositions containing isoflavones - Google Patents
Pharmaceutical compositions containing isoflavonesInfo
- Publication number
- IL128765A0 IL128765A0 IL12876597A IL12876597A IL128765A0 IL 128765 A0 IL128765 A0 IL 128765A0 IL 12876597 A IL12876597 A IL 12876597A IL 12876597 A IL12876597 A IL 12876597A IL 128765 A0 IL128765 A0 IL 128765A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- containing isoflavones
- isoflavones
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO2039A AUPO203996A0 (en) | 1996-08-30 | 1996-08-30 | Therapeutic uses |
PCT/AU1997/000563 WO1998008503A1 (en) | 1996-08-30 | 1997-08-29 | Therapeutic methods and compositions involving isoflavones |
Publications (1)
Publication Number | Publication Date |
---|---|
IL128765A0 true IL128765A0 (en) | 2000-01-31 |
Family
ID=3796352
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12876597A IL128765A0 (en) | 1996-08-30 | 1997-08-29 | Pharmaceutical compositions containing isoflavones |
IL128765A IL128765A (en) | 1996-08-30 | 1999-03-01 | Pharmaceutical compositions containing isoflavones |
IL181059A IL181059A (en) | 1996-08-30 | 2007-01-30 | Pharmaceutical compositions containing isoflavones |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL128765A IL128765A (en) | 1996-08-30 | 1999-03-01 | Pharmaceutical compositions containing isoflavones |
IL181059A IL181059A (en) | 1996-08-30 | 2007-01-30 | Pharmaceutical compositions containing isoflavones |
Country Status (16)
Country | Link |
---|---|
US (8) | US6649648B1 (hu) |
EP (2) | EP0954302A4 (hu) |
JP (2) | JP2001500480A (hu) |
CN (5) | CN101007000B (hu) |
AU (1) | AUPO203996A0 (hu) |
BR (1) | BRPI9713180B1 (hu) |
CA (1) | CA2265049A1 (hu) |
CZ (1) | CZ295625B6 (hu) |
GB (1) | GB2331015B (hu) |
HK (4) | HK1019553A1 (hu) |
HU (1) | HUP9903971A3 (hu) |
IL (3) | IL128765A0 (hu) |
NO (3) | NO325681B1 (hu) |
NZ (2) | NZ506063A (hu) |
TR (1) | TR199900885T2 (hu) |
WO (1) | WO1998008503A1 (hu) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT656786E (pt) | 1992-05-19 | 2004-11-30 | Novogen Res Pty Ltd | Utilizacao de extractos do fitoestrogenio isoflavona de soja ou trevo |
AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
AU7165798A (en) * | 1997-04-28 | 1998-11-24 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
CA2287965C (en) * | 1997-05-01 | 2009-10-20 | Graham Edmund Kelly | Treatment or prevention of menopausal symptoms and osteoporosis |
AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
CA2323364A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions for regulating skin appearance |
JPH11269066A (ja) * | 1998-03-20 | 1999-10-05 | Kao Corp | 経口用美白剤及び美白用食品 |
AUPP260798A0 (en) * | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
AU4204099A (en) * | 1998-05-27 | 1999-12-13 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of migraine headaches |
US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
GB9814620D0 (en) * | 1998-07-06 | 1998-09-02 | Karobio Ab | Vasculoprotector |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
FR2781154B1 (fr) * | 1998-07-15 | 2001-09-07 | Lafon Labor | Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques |
AU5440799A (en) * | 1998-09-17 | 2000-04-10 | Guido Schnyder | Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
AUPP868599A0 (en) * | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
US20040072765A1 (en) * | 1999-04-28 | 2004-04-15 | Novogen Research Pty Ltd. | Cardiovascular and bone treatment using isoflavones |
AUPQ266199A0 (en) * | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
AUPQ520300A0 (en) * | 2000-01-21 | 2000-02-17 | Novogen Research Pty Ltd | Food product and process |
EP1132084A1 (en) * | 2000-03-06 | 2001-09-12 | Docteur Nature Srl | Transdermal device for the slow release of soybean derived vegetable estrogens |
AU2001253070A1 (en) * | 2000-03-31 | 2001-10-15 | Jonathan Ingram | Isoflavones for treatment of obesity |
CA2412501C (en) | 2000-06-12 | 2011-05-31 | The Government Of The United States Of America, As Represented By The Se | Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
US6248790B1 (en) | 2000-06-29 | 2001-06-19 | Parker Hughes Institute | Treatment of inflammation with 2,4,6-trihydroxy-alpha-rho-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives |
ES2309030T3 (es) | 2000-08-16 | 2008-12-16 | Unilever N.V. | Mezclas de isoflanonas y flavonas. |
AUPQ968700A0 (en) * | 2000-08-28 | 2000-09-21 | Intreat Pty Limited | Treatment of urinary incontinence |
FR2815033B1 (fr) * | 2000-10-06 | 2003-09-05 | Negma Lab | Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
AUPR363301A0 (en) * | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
JP4256679B2 (ja) * | 2001-03-16 | 2009-04-22 | ノボゲン リサーチ ピーティーワイ リミテッド | 再狭窄の治療方法 |
AU2006200292B2 (en) * | 2001-03-16 | 2007-11-22 | Novogen Research Pty Ltd | Treatment of restenosis |
US20050119301A1 (en) * | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
DE10114305A1 (de) * | 2001-03-23 | 2002-09-26 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Isoflavonen und Verwendung von Isoflavonen zur Herstellung kosmetischer und dermatologischer Zubereitungen zur Reduktion des Sebumgehaltes der Haut |
US6787151B2 (en) | 2001-08-10 | 2004-09-07 | Lipton, Division Of Conopco, Inc. | Composition for lowering blood cholesterol |
AUPR846401A0 (en) * | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
MXPA04009896A (es) * | 2002-04-09 | 2005-06-17 | Novogen Res Pty Ltd | Metodos terapeuticos y composiciones que implican estructuras de tipo isoflav-3-eno e isoflavano. |
US8668914B2 (en) * | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
EP2526940A3 (en) | 2002-07-24 | 2014-07-30 | Children's Hospital Medical Center | Compositions containing enantiomeric equol, and methods for their making |
AU2002951271A0 (en) * | 2002-09-06 | 2002-09-19 | Novogen Research Pty Ltd | Repair of dna mutagenic damage |
AU2003257264B2 (en) * | 2002-09-06 | 2007-09-13 | Novogen Research Pty Ltd | Repair of DNA mutagenic damage |
AU2003264176B2 (en) * | 2002-09-23 | 2008-12-11 | Novogen Research Pty Ltd | Skin photoageing and actinic damage treatment |
US20060153782A1 (en) * | 2002-09-23 | 2006-07-13 | Novogen Research Pty Ltd | Skin photoageing and actinic damage treatment |
AU2002951833A0 (en) | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
CA2504682A1 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US20070244075A1 (en) * | 2003-11-18 | 2007-10-18 | Novogen Research Pty Ltd | Isoflavonoid Prodrugs, Compositons Thereof and Therapeutic Methods Involving Same |
US20060167037A1 (en) * | 2003-11-19 | 2006-07-27 | Kelly Graham E | Combinational radiotherapy and chemotherapy compositions and methods |
US20050143323A1 (en) * | 2003-12-30 | 2005-06-30 | Henley E. C. | Isoflavone therapy for treating urinary incontinence |
JP2005289817A (ja) * | 2004-03-09 | 2005-10-20 | Daicho Kikaku:Kk | 抗癌剤 |
EP1740191A4 (en) | 2004-04-28 | 2008-07-30 | Univ Brigham Young | USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES |
CN100351248C (zh) * | 2004-07-05 | 2007-11-28 | 南京大学 | 染料木素衍生物及其制法和用途 |
EP2436680B1 (en) | 2004-09-21 | 2016-05-18 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
EP1794141B1 (en) | 2004-09-21 | 2011-11-09 | Marshall Edwards, Inc. | Substituted chroman derivatives, medicaments and use in therapy |
US20060189543A1 (en) * | 2005-02-23 | 2006-08-24 | Rosenbloom Richard A | Compositions and methods for the treatment of leukemia |
JP2008533177A (ja) * | 2005-03-24 | 2008-08-21 | ノボジェン リサーチ ピーティーワイ リミテッド | 抗炎症治療法 |
US7528267B2 (en) | 2005-08-01 | 2009-05-05 | Girindus America, Inc. | Method for enantioselective hydrogenation of chromenes |
ES2542989T3 (es) | 2005-10-12 | 2015-08-13 | Idera Pharmaceuticals, Inc. | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
EP2474237B1 (en) | 2005-12-06 | 2018-04-25 | Otsuka Pharmaceutical Co., Ltd. | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof |
EP2084141A4 (en) * | 2006-10-30 | 2010-07-21 | Novogen Res Pty Ltd | PREVENTION AND REVERSION OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
CN102143744B (zh) * | 2008-07-25 | 2016-08-31 | 爱默蕾大学 | 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途 |
KR20110071108A (ko) * | 2008-10-06 | 2011-06-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도 |
EP2365955B1 (en) * | 2008-11-14 | 2014-12-31 | Heartlink Limited | Aryl di-substituted propenone compounds |
CN101716135B (zh) * | 2010-01-08 | 2012-11-14 | 山西医科大学 | 大豆异黄酮固体分散体栓剂及其制备方法 |
EP2579870B1 (en) | 2010-06-09 | 2018-02-14 | Emory University | Trkb agonists and methods of use |
US9663484B2 (en) | 2010-11-01 | 2017-05-30 | Mei Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
MX340363B (es) | 2010-11-19 | 2016-07-06 | Idera Pharmaceuticals Inc | Compuestos de oligonucleotidos inmuno-reguladores (iro) que modulan la respuesta inmune basada en receptores tipo toll. |
CN102503922A (zh) * | 2011-11-07 | 2012-06-20 | 吉首大学 | 黄烷醇(异黄烷醇)类尿素酶抑制剂及其合成和用途 |
CN103127053B (zh) * | 2011-11-22 | 2014-05-21 | 沈阳药科大学 | 6-[2-(二甲氨基)乙氧基]黄酮的医药用途 |
CA2863710A1 (en) * | 2012-02-29 | 2013-09-06 | Avon Products, Inc. | Use of cpt-1 modulators and compositions thereof |
CN102784135B (zh) * | 2012-07-05 | 2014-11-05 | 西安交通大学 | 基于雌马酚激活BKCa通道的应用 |
WO2014018741A1 (en) | 2012-07-27 | 2014-01-30 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
CN102846595B (zh) * | 2012-09-21 | 2013-08-28 | 沈阳药科大学 | 黄酮类化合物wx-03用于舒张血管平滑肌的用途 |
CN103030647B (zh) * | 2013-01-16 | 2014-10-29 | 山东省分析测试中心 | 一种光甘草定的合成方法 |
WO2014165723A2 (en) | 2013-04-04 | 2014-10-09 | The Administrators Of The Tulane Educational Fund | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells |
JP6371055B2 (ja) * | 2013-12-20 | 2018-08-08 | 株式会社ダイセル | イソフラバノン類の製造方法 |
CN105777693A (zh) * | 2014-12-22 | 2016-07-20 | 王靖林 | 一种雌马酚的合成方法 |
CN116139125A (zh) | 2015-02-02 | 2023-05-23 | 梅制药公司 | 联合治疗 |
US11000472B2 (en) * | 2015-04-06 | 2021-05-11 | Lg Household & Health Care Ltd. | Soluble microneedle for delivering poorly-soluble drug |
CN105153094B (zh) * | 2015-07-08 | 2017-09-15 | 江苏省中国科学院植物研究所 | 碱蓬黄酮c及其制备方法和用途 |
JP2019513827A (ja) * | 2016-04-06 | 2019-05-30 | ノクソファーム リミティド | 標的化薬物送達 |
CA3058492A1 (en) * | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Radiotherapy improvements |
EP4005567A1 (en) | 2016-04-06 | 2022-06-01 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
SG11201808777UA (en) | 2016-04-06 | 2018-11-29 | Noxopharm Ltd | Improvements in cancer treatment |
US20190117620A1 (en) | 2016-04-22 | 2019-04-25 | Noxopharm Limited | Chemotherapy improvements |
CN108409701B (zh) * | 2017-02-10 | 2020-09-25 | 山东康迈祺生物科技有限公司 | 一种二氢大豆苷元的制备方法 |
CN110590727A (zh) * | 2019-09-16 | 2019-12-20 | 西安联泽生物科技有限公司 | 一种雌马酚的制备方法 |
EP4125870A1 (en) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US498631A (en) * | 1893-05-30 | Nut-lock | ||
US35074A (en) * | 1862-04-29 | Improvement bn snow-plows for railroads | ||
DE1518002C3 (de) | 1965-01-02 | 1975-01-23 | Merck Patent Gmbh, 6100 Darmstadt | Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel |
DE1543749A1 (de) * | 1966-02-16 | 1969-12-11 | Merck Ag E | Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen |
JPS54734B2 (hu) | 1973-05-14 | 1979-01-16 | ||
US3973608A (en) * | 1973-08-01 | 1976-08-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Microbial production of certain isoflavones |
US3886278A (en) * | 1973-08-22 | 1975-05-27 | Mead Johnson & Co | Ammonium carboxylate sebum inhibition process |
US4061779A (en) * | 1973-09-11 | 1977-12-06 | Beecham Group Limited | Naphthalene derivatives having anti-inflammatory activity |
JPS576427B2 (hu) | 1974-01-25 | 1982-02-04 | ||
HU168753B (hu) | 1974-05-03 | 1976-07-28 | ||
JPS50160483A (hu) | 1974-06-19 | 1975-12-25 | ||
GB1495189A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 4-oxo-4h-benzopyran derivatives and process for their preparation |
DE2643800C2 (de) * | 1976-09-29 | 1986-10-30 | Fritz Werner Industrie-Ausrüstungen GmbH, 6222 Geisenheim | Verfahren zur Herstellung von Xylose durch enzymatische Hydrolyse von Xylanen |
US4157984A (en) * | 1977-06-08 | 1979-06-12 | Z-L Limited | Antioxidants, antioxidant compositions and methods of preparing and using same |
US4264509A (en) * | 1977-06-08 | 1981-04-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
SU907060A1 (ru) * | 1979-02-07 | 1982-02-23 | Всесоюзный Научно-Исследовательский Биотехнический Институт | Способ получени розового масла |
US4390559A (en) | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4366082A (en) * | 1979-04-11 | 1982-12-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
JPS5933232A (ja) * | 1982-08-19 | 1984-02-23 | Tokiwa Kanpou Seiyaku:Kk | マメ科植物からサポニン類およびフラボン類の分離方法 |
JPS59199630A (ja) | 1983-04-26 | 1984-11-12 | Takeda Chem Ind Ltd | 卵巣機能低下症治療剤 |
JPS6048924A (ja) * | 1983-08-24 | 1985-03-16 | Takeda Chem Ind Ltd | 骨粗鬆症治療剤 |
JPS6054379A (ja) | 1983-09-05 | 1985-03-28 | Takeda Chem Ind Ltd | 新規4h−1−ベンゾピラン−4−オン誘導体,その製法および用途 |
JPS60132976A (ja) * | 1983-12-21 | 1985-07-16 | Takeda Chem Ind Ltd | 新規3−フエニル−4h−1−ベンゾピラン−4−オン誘導体 |
US4484013A (en) * | 1983-12-30 | 1984-11-20 | Uop Inc. | Process for coproduction of isopropanol and tertiary butyl alcohol |
US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
JPS61246124A (ja) | 1985-04-24 | 1986-11-01 | Yamanouchi Pharmaceut Co Ltd | 制癌剤 |
JPS61247396A (ja) * | 1985-04-24 | 1986-11-04 | Yamanouchi Pharmaceut Co Ltd | ゲニステインの製造法 |
JPS62106016A (ja) * | 1985-11-01 | 1987-05-16 | Yamanouchi Pharmaceut Co Ltd | 免疫抑制剤 |
JPS62106017A (ja) * | 1985-11-01 | 1987-05-16 | Yamanouchi Pharmaceut Co Ltd | 抗腫瘍剤 |
JPS62126186A (ja) | 1985-11-28 | 1987-06-08 | Tsumura Juntendo Inc | イソフラボン誘導体含有溶液の製造方法 |
GB8626344D0 (en) | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
JPS6442427A (en) | 1987-08-10 | 1989-02-14 | Tsumura & Co | Sialidase inhibitor |
JPH0832632B2 (ja) | 1988-03-08 | 1996-03-29 | 株式会社太田胃散 | 尿素窒素代謝改善剤 |
JPH0714927B2 (ja) | 1988-04-06 | 1995-02-22 | キッコーマン株式会社 | イソフラボン化合物の製造法 |
US4950475A (en) * | 1988-07-19 | 1990-08-21 | Imaginative Research Associates, Inc. | Novel film-forming gels with high concentrations of humectants and emollients |
JPH0267218A (ja) * | 1988-08-31 | 1990-03-07 | Nagakura Seiyaku Kk | ウイルス・ゲノム不活化剤 |
JPH0269165A (ja) | 1988-09-02 | 1990-03-08 | Mitsugi Ohashi | 癌抑制食品 |
JPH02124883A (ja) | 1988-11-04 | 1990-05-14 | Kitasato Inst:The | 抗酸化作用を有するイソフラボン誘導体およびその製造法 |
JP2753719B2 (ja) | 1988-12-15 | 1998-05-20 | 日本油脂株式会社 | リポソーム製剤の製造法 |
JPH02193919A (ja) * | 1989-01-23 | 1990-07-31 | Kao Corp | 皮脂線抑制剤 |
JPH0347049A (ja) | 1989-03-09 | 1991-02-28 | Sanyu:Kk | 豆腐廃液ゆからの食品素材及び健康飲料の製造方法 |
US5153230A (en) | 1989-10-06 | 1992-10-06 | Perfective Cosmetics, Inc. | Topical skin cream composition |
CH679584A5 (hu) | 1989-11-10 | 1992-03-13 | Nestle Sa | |
IT1241079B (it) | 1990-03-23 | 1993-12-29 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico |
KR0149172B1 (ko) * | 1990-04-06 | 1998-10-15 | 기율라스주크, 타마스스주츠 | 치환 이소플라본 유도체의 개량된 제조방법 |
US5489524A (en) * | 1991-03-26 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein that has a human Rho motif and deoxyribonuclease activity |
JP2799254B2 (ja) * | 1991-07-11 | 1998-09-17 | 三菱電機株式会社 | 半導体装置の製造方法 |
JPH0517056A (ja) * | 1991-07-12 | 1993-01-26 | Ricoh Co Ltd | ロール紙カセツト |
GB2261671B (en) * | 1991-11-16 | 1996-07-03 | Gb Biotech | Gel production from plant matter |
JPH05170756A (ja) | 1991-12-20 | 1993-07-09 | Kikkoman Corp | イソフラボン化合物の製造法 |
PT656786E (pt) | 1992-05-19 | 2004-11-30 | Novogen Res Pty Ltd | Utilizacao de extractos do fitoestrogenio isoflavona de soja ou trevo |
JP3241440B2 (ja) * | 1992-07-02 | 2001-12-25 | 有限会社野々川商事 | 化粧料 |
FR2693724B1 (fr) | 1992-07-17 | 1994-10-07 | Lipha | Utilisation de composés benzopyraniques ou benzothiopyraniques pour l'induction de l'expression des gènes de la nodulation des bactéries du genre Rhizobium associées aux légumineuses. |
JPH0640909A (ja) | 1992-07-23 | 1994-02-15 | Kobe Steel Ltd | スーパーオキシド・ディスムターゼ様活性剤 |
JPH0640876A (ja) | 1992-07-23 | 1994-02-15 | Kobe Steel Ltd | 紫外線障害防御外用剤 |
JPH0686682A (ja) | 1992-07-23 | 1994-03-29 | Kobe Steel Ltd | 4’,7,8−トリヒドロキシイソフラボンの製造方法 |
DE4236237A1 (de) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
AU6635994A (en) | 1993-04-16 | 1994-11-08 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
JPH06321752A (ja) | 1993-05-07 | 1994-11-22 | Kao Corp | 美白剤 |
US5595970A (en) * | 1993-07-16 | 1997-01-21 | Schering Aktiengesellschaft | Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
AU680554B2 (en) * | 1993-10-12 | 1997-07-31 | Archer-Daniels-Midland Company | An aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing |
US5320949A (en) * | 1993-10-12 | 1994-06-14 | Protein Technologies International, Inc. | Process for producing aglucone isoflavone enriched vegetable protein fiber |
BR9407792A (pt) * | 1993-10-12 | 1997-03-18 | Protein Tech Int | Processo para produção de um extrato enriquecido com isoflavona de aglucona de um material de proteina vegetal extrato enriquecido com isoflavona de aglucona isolado de proteina enriquecido com isoflavona de aglucona isolado de proteina vegetal e processo para recuperação de pelo menos 50% de uma isoflavona de um material de proteina vegetal |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
JP3078694B2 (ja) * | 1993-12-17 | 2000-08-21 | キッコーマン株式会社 | ゲニステインの製造法 |
IL112061A (en) * | 1994-01-13 | 1999-10-28 | Bristol Myers Squibb Co | Methods for the preparation of taxanes |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
IL112639A0 (en) | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
US5424331A (en) * | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
US5547866A (en) * | 1994-07-20 | 1996-08-20 | The Regents Of The University Of California | Taxane production in haploid-derived cell cultures |
DE4432947C2 (de) * | 1994-09-16 | 1998-04-09 | New Standard Gmbh | Mittel zur Behandlung der Haut und seine Verwendung |
WO1996010341A1 (en) * | 1994-10-03 | 1996-04-11 | Schouten Industries B.V. | Food and health products |
US5637598A (en) * | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
US5516528A (en) * | 1995-01-13 | 1996-05-14 | Wake Forest University | Dietary phytoestrogen in estrogen replacement therapy |
US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5679806A (en) * | 1995-02-24 | 1997-10-21 | Hauser, Inc. | Process for the isolation and purification of isoflavones |
JPH08283283A (ja) * | 1995-04-14 | 1996-10-29 | Kikkoman Corp | マロニルイソフラボン配糖体及び該物質からイソフラボン配糖体又はイソフラボンアグリコンを取得する方法 |
WO1996039832A1 (en) * | 1995-06-07 | 1996-12-19 | Kung Patrick C | Compounds and methods for promoting hair growth |
EP0873142A4 (en) * | 1995-06-07 | 2001-08-08 | Sugen Inc | CONNECTION TESTING TESTS |
US5639785A (en) | 1995-06-07 | 1997-06-17 | Global Pharma, Ltd. | Methods for the treatment of baldness and gray hair using isoflavonoid derivatives |
US5554519A (en) * | 1995-08-07 | 1996-09-10 | Fermalogic, Inc. | Process of preparing genistein |
JPH0967362A (ja) | 1995-09-01 | 1997-03-11 | Sankyo Co Ltd | 5α−還元酵素阻害剤ビスイソフラボン類 |
US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
US5702752A (en) * | 1996-03-13 | 1997-12-30 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
US5821361A (en) | 1996-06-11 | 1998-10-13 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
JPH1059956A (ja) | 1996-08-22 | 1998-03-03 | Kikkoman Corp | 新規イソフラボン誘導体及びその製造法 |
AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US5726034A (en) * | 1996-09-06 | 1998-03-10 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same |
US5804234A (en) * | 1996-09-13 | 1998-09-08 | Suh; John D. | Plant protein for nutritional products and method of making same |
US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
CA2287965C (en) | 1997-05-01 | 2009-10-20 | Graham Edmund Kelly | Treatment or prevention of menopausal symptoms and osteoporosis |
US6060070A (en) | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
AUPP112497A0 (en) | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
US6004558A (en) | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
US6132795A (en) | 1998-03-15 | 2000-10-17 | Protein Technologies International, Inc. | Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material |
CA2323364A1 (en) | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions for regulating skin appearance |
AUPP260798A0 (en) | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
US6544566B1 (en) | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
-
1996
- 1996-08-30 AU AUPO2039A patent/AUPO203996A0/en not_active Abandoned
-
1997
- 1997-08-29 EP EP97937345A patent/EP0954302A4/en not_active Withdrawn
- 1997-08-29 BR BRPI9713180A patent/BRPI9713180B1/pt not_active IP Right Cessation
- 1997-08-29 CN CN2007100016758A patent/CN101007000B/zh not_active Expired - Fee Related
- 1997-08-29 CN CN2007100016743A patent/CN101006999B/zh not_active Expired - Fee Related
- 1997-08-29 GB GB9902141A patent/GB2331015B/en not_active Expired - Fee Related
- 1997-08-29 EP EP07102112A patent/EP1927352A3/en not_active Withdrawn
- 1997-08-29 TR TR1999/00885T patent/TR199900885T2/xx unknown
- 1997-08-29 IL IL12876597A patent/IL128765A0/xx active IP Right Grant
- 1997-08-29 CZ CZ1999699A patent/CZ295625B6/cs not_active IP Right Cessation
- 1997-08-29 NZ NZ506063A patent/NZ506063A/xx unknown
- 1997-08-29 CN CNA2007100016762A patent/CN101007001A/zh active Pending
- 1997-08-29 CN CNB971986908A patent/CN1301710C/zh not_active Expired - Fee Related
- 1997-08-29 CA CA002265049A patent/CA2265049A1/en not_active Abandoned
- 1997-08-29 NZ NZ334025A patent/NZ334025A/xx unknown
- 1997-08-29 WO PCT/AU1997/000563 patent/WO1998008503A1/en not_active Application Discontinuation
- 1997-08-29 CN CNA2004100485460A patent/CN1559401A/zh active Pending
- 1997-08-29 US US09/254,026 patent/US6649648B1/en not_active Expired - Lifetime
- 1997-08-29 JP JP10511105A patent/JP2001500480A/ja active Pending
- 1997-08-29 HU HU9903971A patent/HUP9903971A3/hu unknown
-
1999
- 1999-02-26 NO NO19990965A patent/NO325681B1/no not_active IP Right Cessation
- 1999-03-01 IL IL128765A patent/IL128765A/en not_active IP Right Cessation
- 1999-10-21 HK HK99104669A patent/HK1019553A1/xx not_active IP Right Cessation
-
2000
- 2000-03-03 HK HK00101374A patent/HK1022425A1/xx not_active IP Right Cessation
-
2002
- 2002-06-21 US US10/177,387 patent/US20030018060A1/en not_active Abandoned
- 2002-06-21 US US10/176,762 patent/US7202273B2/en not_active Expired - Fee Related
-
2003
- 2003-08-06 US US10/636,902 patent/US20050059616A1/en not_active Abandoned
-
2004
- 2004-12-28 US US11/024,512 patent/US7419998B2/en not_active Expired - Fee Related
-
2006
- 2006-05-01 US US11/415,950 patent/US20060286150A1/en not_active Abandoned
-
2007
- 2007-01-30 IL IL181059A patent/IL181059A/en not_active IP Right Cessation
- 2007-10-04 HK HK07110769.1A patent/HK1105580A1/xx not_active IP Right Cessation
- 2007-10-08 NO NO20075066A patent/NO20075066L/no not_active Application Discontinuation
- 2007-10-08 NO NO20075065A patent/NO20075065L/no not_active Application Discontinuation
-
2008
- 2008-01-30 HK HK08101165.9A patent/HK1112180A1/xx not_active IP Right Cessation
- 2008-07-22 US US12/177,843 patent/US7915308B2/en not_active Expired - Fee Related
- 2008-12-04 JP JP2008309525A patent/JP5268601B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-06 US US13/102,805 patent/US20110212989A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL181059A0 (en) | Pharmaceutical compositions containing isoflavones | |
EG24118A (en) | Pharmaceutical compositions | |
GB9727053D0 (en) | Pharmaceutical compositions | |
CY2569B1 (en) | Pharmaceutical compositions | |
GB9616672D0 (en) | Pharmaceutical compositions | |
ZA9710006B (en) | Novel pharmaceutical compositions | |
GB9610359D0 (en) | Pharmaceutical compositions | |
IL131995A0 (en) | Gastric-retained pharmaceutical compositions | |
ZA9710919B (en) | Pharmaceutical compositions containing N-sulphony-lindole derivatives | |
GB9723985D0 (en) | Pharmaceutical compositions | |
ZA979726B (en) | Pharmaceutical compositions | |
HUP0004669A3 (en) | Pharmaceutical compositions | |
GB9606429D0 (en) | Pharmaceutical compositions | |
GB9613457D0 (en) | Pharmaceutical compositions | |
HU9700632D0 (en) | Pharmaceutical compositions | |
GB9623962D0 (en) | Pharmaceutical composition | |
GB9618376D0 (en) | Pharmaceutical compositions | |
GB9610136D0 (en) | Pharmaceutical compositions | |
HUP0003528A3 (en) | Pharmaceutical compositions containing dihydropolyprenols | |
GB9921495D0 (en) | Pharmaceutical compositions | |
IL132784A0 (en) | Pharmaceutical compositions containing dronabinol | |
GB9603942D0 (en) | Pharmaceutical compositions | |
GB9606586D0 (en) | Pharmaceutical compositions | |
GB9623225D0 (en) | Novel pharmaceutical compositions | |
SI0941095T1 (en) | Improved pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |